Table 1.
Characteristics of the 2272 AML patients ≥70 years according to treatment.
| Intensive chemotherapy N = 1199 (52.8%) | Hypomethylating agents N = 1073 (47.2%) | P value | All patients N = 2272 (100%) | |
|---|---|---|---|---|
| Study period – no. (%) | ||||
| 2007–2012 | 532 (44.4) | 346 (32.2) | < 0.001 | 878 (38.6) |
| 2013–2018 | 667 (55.6) | 727 (67.8) | 1394 (61.4) | |
| Sex – no. (%) | ||||
| Male | 669 (55.8) | 611 (57.0) | 0.563 | 1280 (56.4) |
| Female | 529 (44.2) | 460 (43.0) | 989 (43.6) | |
| Age – years | ||||
| Median (IQR) | 74.0 (72.0–76.0) | 77.5 (74.0–81.1) | <0.001 | 75.0 (72.5–79.0) |
| <75 y – no. (%) | 740 (61.7) | 331 (30.8) | 1071 (47.1) | |
| ≥75 y – no. (%) | 459 (38.3) | 742 (69.2) | 1201 (52.9) | |
| ECOG performance status – no. (%) | ||||
| 0–1 | 846 (74.9) | 651 (68.2) | <0.001 | 1497 (71.8) |
| 2–4 | 283 (25.1) | 304 (31.8) | 587 (28.2) | |
| AML status – no. (%) | ||||
| De novo | 848 (75.3) | 572 (58.7) | <0.001 | 1420 (67.6) |
| Secondary | 278 (24.7) | 402 (41.3) | 680 (32.4) | |
| White blood cell count – giga per liter | ||||
| Median (IQR) | 9.3 (2.3–54.0) | 3.5 (1.8–12.3) | <0.001 | 5.2 (2.0–27.3) |
| ≤30 – no. (%) | 784 (66.4) | 923 (88.3) | 1707 (76.7) | |
| >30 – no. (%) | 396 (33.6) | 122 (11.7) | 518 (23.3) | |
| Peripheral blasts – % | ||||
| Median (IQR) | 30.0 (6.0–71.0) | 10.0 (2.0–33.0) | <0.001 | 19.0 (3.0–56.0) |
| Bone marrow blasts - % | ||||
| Median (IQR) | 61.0 (38.0–82.0) | 36.0 (25.0–60.0) | <0.001 | 50.0 (30.0–75.0) |
| LDH – IU/liter | ||||
| Median (IQR) | 429.0 (258.0–736.0) | 396.3 (239.4–600.0) | <0.001 | 396.0 (248.0–676.0) |
| Cytogenetic risk – no. (%) | ||||
| Favorable | 47 (4.4) | 9 (1.0) | <0.001 | 56 (2.9) |
| Intermediate | 795 (75.2) | 518 (59.6) | 1313 (68.2) | |
| Adverse | 215 (20.3) | 342 (39.4) | 557 (28.9) | |
| NPM1 mutations | ||||
| No | 553 (64.4) | 390 (81.2) | <0.001 | 943 (70.4) |
| Yes | 306 (35.6) | 90 (18.8) | 396 (29.6) | |
| FLT3-ITD mutations – no. (%) | ||||
| No | 698 (80.2) | 463 (91.0) | <0.001 | 1161 (84.2) |
| Yes | 172 (19.8) | 46 (9.0) | 0.232 | 218 (15.8) |
| Allelic ratio – no | 134 | 40 | 174 | |
| Median (IQR) | 0.6 (0.3–0.8) | 0.4 (0.2–0.9) | 0.6 (0.3–0.9) | |
| IDH1-R132 mutations – no. (%) | ||||
| No | 187 (90.8) | 239 (89.5) | 0.649 | 426 (90.1) |
| Yes | 19 (9.2) | 28 (10.5) | 47 (9.9) | |
| IDH2-R140 mutations – no. (%) | ||||
| No | 178 (86.4) | 234 (88.3) | 0.538 | 412 (87.5) |
| Yes | 28 (13.6) | 31 (11.7) | 59 (12.5) | |
| IDH2-R172 mutations – no. (%) | ||||
| No | 204 (98.6) | 257 (97.7) | 0.737 | 461 (98.1) |
| Yes | 3 (1.4) | 6 (2.3) | 9 (1.9) | |
| Inclusion in a clinical trial – no. (%) | ||||
| No | 1058 (88.2) | 863 (80.4) | <0.001 | 1921 (84.6) |
| Yes | 141 (11.8) | 210 (19.6) | 351 (15.4) | |
| Allogeneic stem cell transplantation – no. (%) | ||||
| No | 1129 (94.2) | 1066 (99.3) | <0.001 | 2195 (96.6) |
| Yes | 70 (5.8) | 7 (0.7) | 77 (3.4) | |